News

ABL launches its Life Science division and starts the distribution of disruptive molecular biology instruments to be used for research purposes – Join our Early Access Program and get 30% discount on all UltraGene real time PCR systems! More information Join the program

Advanced Biological Laboratories (ABL) S.A. and ILC – Instrumentos de Laboratório e Científicos Lda are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Portugal. See current ch…

LUXEMBOURG VILLE, Luxembourg, December 27th, 2018 — Advanced Biological Laboratories (ABL) S.A. today announced the official launch of its Life Science division to provide on a worldwide basis, innovative solutions around molecular biology. It is also proud to announce the execution of a distr…

Advanced Biological Laboratories (ABL) S.A. and ELTA 90 Medical Science are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Serbia and Montenegro. See current channel partners.

New poster on HIV resistance to be presented at the HIV DART 2018 congress

We are pleased to announce that a new poster communication entitled “Clinical resistance to dolutegravir assessed by next-generation sequencing in patients pre-exposed to raltegravir” will be presented at the HIV DART and Emerging Viruses 2018 congress in Miami (USA, 27-29 November 2018)…

Advanced Biological Laboratories (ABL) S.A. and Bio-Active Co., Ltd. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Thailand. See current channel partners.

ABL is pleased to announce the validation of its DeepChek® Line of Assays on the Applied Biosystems SeqStudio Genetic Analyzer. Download the technical note for more information.

ABL will be attending the next MEDICA forum in Dusseldorf from 12 – 15 November 2018: Hall 3 / B70 Our team will provide information on our portfolio: Laboratories, virologists and microbiologists: DeepChek® Assays (Genotyping & Drug Resistance) UltraGene® Assays (Viral Load Detection) Dee…

We are pleased to announce that, after 2015 and 2016, the DeepChek®-HIV RT/PROT assay and the DeepChek®-HIV INT assay successfully passed a national quality control program in France, Switzerland and emerging countries (ANRS CQ 2017) through an independent lab and obtained 100% positive results on s…

ABL is pleased to announce the validation of its DeepChek® Line of Assays on the Illumina iSeq 100 Sequencing System. Download the technical note for more information.

ABL is pleased to announce the immediate availability of a new DeepChek® Assay intended to be used for Herpes Simplex Virus (HSV) genotyping and for determining the presence of mutations within UL23 (thymidine kinase) and UL30 (DNA polymerase) conferring drug resistance to antiviral drugs – DE…

CDL Pharma, an ABL Group’s affiliate, obtained the renewal of conformity certification of its Quality System, in compliance with the standard UNI EN ISO 9001:2015. We focus to provide our customers high quality products and services which satisfy all requirements from applicable regulations an…

We are delighted to announce you that Advanced Biological Laboratories (ABL – https://www.ablsa.com) has just signed a definitive agreement to acquire CDL Pharma (http://www.cdlpharma.com/), a company headquartered in France – see the full press release. CDL Pharma Provides comprehensive biolo…

VHIR will collaborate with ABL laboratories in developing software tools

This June, the Consorcio Centro de Investigación Biomédica en Red, M.P. – CIBER, the Advanced Biological Laboratories S.A. – ABL and the Vall d’Hebron Research Institute – VHIR have signed a collaboration agreement to develop an analysis software for the high resolution subtyped results obtained on…

Advanced Biological Laboratories S.A. and Seha Connect IT Solutions LLC enter into an exclusive distribution and development collaboration agreement covering 14 countries in the Middle East region. The agreement is effective immediately and covers a large panel of clinical software developed by ABL…